Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Strong
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Description
Invion Ltd. is a clinical-stage life sciences company, which engages in the research and development of treatment for cancers, atherosclerosis, and infectious diseases. The company was founded on October 11, 2000 and is headquartered in Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.0 - 0.01
Trade Value (12mth)
AU$1,892.00
1 week
-16.67%
1 month
25%
YTD
-50%
1 year
-50%
All time high
0.55
EPS 3 yr Growth
200.00%
EBITDA Margin
-131.60%
Operating Cashflow
-$2m
Free Cash Flow Return
-14.60%
ROIC
-34.30%
Interest Coverage
N/A
Quick Ratio
2.10
Shares on Issue (Fully Dilluted)
6425m
HALO Sector
Healthcare
Next Company Report Date
N/A
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
16 October 24 |
Securities Consolidation Clarification
×
Securities Consolidation Clarification |
15 October 24 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
15 October 24 |
Consolidation/Split - IVX
×
Consolidation/Split - IVX |
19 September 24 |
Investor Presentation
×
Investor Presentation |
18 September 24 |
Ph 2 Prostate Cancer Results Strong Safety and 40% Response
×
Ph 2 Prostate Cancer Results Strong Safety and 40% Response |
11 September 24 |
Ethics Approval for Phase I/II Non-Meloma Skin Cancer Trial
×
Ethics Approval for Phase I/II Non-Meloma Skin Cancer Trial |
11 September 24 |
Application for quotation of securities - IVX
×
Application for quotation of securities - IVX |
11 September 24 |
Section 708A Cleansing Statement
×
Section 708A Cleansing Statement |
09 September 24 |
Application for quotation of securities - IVX
×
Application for quotation of securities - IVX |
09 September 24 |
Section 708A Cleansing Statement
×
Section 708A Cleansing Statement |
09 September 24 |
Change of Director's Interest Notice- Thian Chew
×
Change of Director's Interest Notice- Thian Chew |
09 September 24 |
Change of Director's Interest Notice - Alan Yamashita
×
Change of Director's Interest Notice - Alan Yamashita |
04 September 24 |
Notification of cessation of securities - IVX
×
Notification of cessation of securities - IVX |
04 September 24 |
Initial Director's Interest Notice - Melanie Leydin
×
Initial Director's Interest Notice - Melanie Leydin |
04 September 24 |
Final Director's Interest Notice - Robert Merriel
×
Final Director's Interest Notice - Robert Merriel |
30 August 24 |
Appendix 4E and Annual Report
×
Appendix 4E and Annual Report |
30 August 24 |
Appendix 4G and Corporate Governance Statement
×
Appendix 4G and Corporate Governance Statement |
29 August 24 |
Director Appointment/Resignation
×
Director Appointment/Resignation |
07 August 24 |
Application for quotation of securities - IVX
×
Application for quotation of securities - IVX |
07 August 24 |
Cleansing Statement and Excluded Information
×
Cleansing Statement and Excluded Information |
31 July 24 |
Change of Company Secretary
×
Change of Company Secretary |
30 July 24 |
Activities Report and Appendix 4C
×
Activities Report and Appendix 4C |
01 July 24 |
Notification regarding unquoted securities - IVX
×
Notification regarding unquoted securities - IVX |
01 July 24 |
Change of Share Registry
×
Change of Share Registry |
01 July 24 |
Notification of cessation of securities - IVX
×
Notification of cessation of securities - IVX |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.